GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Standard BioTools Inc.
Standard BioTools (formerly Fluidigm) produces instruments for biological research. Its stock price reflects the company's complex history, its attempts to restructure, and its search for a place in the highly competitive life sciences equipment market.
Share prices of companies in the market segment - Medanalysis
Standard BioTools, formerly Fluidigm, produces innovative instruments and systems for biomedical research, particularly in the area of single-cell analysis. We classify it in the Medical Analysis segment because its technologies accelerate scientific discovery. The graph below illustrates the dynamics of this high-tech and knowledge-intensive market.
Broad Market Index - GURU.Markets
Standard BioTools develops and manufactures innovative biological research instruments, such as single-cell analysis systems. As a key supplier, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with LAB performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
LAB - Daily change in the company's share price Standard BioTools Inc.
Shares of Standard BioTools, a bioscience instrument maker, exhibit high volatility, as measured by change_co. This reflects sensitivity to R&D spending in the biotech sector. This metric is important for analyzing the medical technology sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Medanalysis
Standard BioTools Inc. is a manufacturer of biomedical research instruments. This chart highlights the sector's high volatility. Comparing it to LAB, whose revenue depends on R&D budgets, helps us evaluate it as a barometer of biotech innovation.
Daily change in the price of a broad market stock, index - GURU.Markets
Standard BioTools (formerly Fluidigm) is a manufacturer of biomedical research instruments. Its history exemplifies the challenges and transformations of the high-tech sector. The chart below illustrates overall market volatility, providing context for Standard BioTools's valuation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Standard BioTools Inc.
Standard BioTools Inc.'s year-to-date performance tells the story of the company, formerly known as Fluidigm, trying to find its niche in the biotech research tools market. Its 12-month market cap reflects investor reactions to strategic shifts, new product launches, and efforts to regain the scientific community's trust in its technology.
Annual dynamics of market capitalization of the market segment - Medanalysis
Standard BioTools, following its merger with SomaLogic, has become a leader in proteomics tools. Its technologies enable scientists to study proteins on an unprecedented scale. The chart below shows how the market perceives the synergies from this acquisition and the potential of its platform for future scientific discoveries.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Standard BioTools, with its life sciences analysis tools, is undergoing a transformation. Its stock price reflects not so much stable demand from science as its success in restructuring and the search for profitability. This chart tells the story of how the tech company is trying to find a new path to growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Standard BioTools Inc.
The performance of Standard BioTools, a manufacturer of biomedical research instruments, depends on R&D budgets. The monthly fluctuations on the chart reflect demand for its cell and protein analysis systems from scientific laboratories and biotech companies.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Standard BioTools, formerly known as Fluidigm, creates innovative tools for biological research, enabling scientists to analyze cells and tissues with high accuracy. Their products accelerate scientific discovery. The graph below shows the overall dynamics of the medical analytical systems sector, which is dependent on funding from science and biotechnology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biomedical research equipment manufacturers are dependent on pharmaceutical R&D budgets. The chart below shows the overall market sentiment. Does Standard BioTools follow these cycles, or does its niche technology create its own demand, independent of the market?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Standard BioTools Inc.
Standard BioTools, a manufacturer of biological research instruments, is responding to news from the scientific world. Its weekly stock price reflects demand from pharmaceutical and biotech companies for cell and protein analysis equipment.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Standard BioTools, like other providers of biomedical research instruments, reflects general trends in scientific funding. Pharmaceutical companies' R&D budgets and government grants create a common demand for all players. The chart shows whether LAB is moving in step with the industry or whether its recent restructurings are creating a different story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Standard BioTools, as a healthcare company, can demonstrate defensive qualities. Demand for its research instruments is less dependent on economic cycles. The chart will help assess whether LAB truly is a safe haven during general market turbulence or whether its restructuring is creating its own dynamics.
Market capitalization of the company, segment and market as a whole
LAB - Market capitalization of the company Standard BioTools Inc.
The Standard BioTools chart tells the story of creating tools for biological research. The company produces cell and protein analysis systems used in scientific laboratories. Its market capitalization reflects how investors view the demand for these sophisticated tools and its ability to compete in the life sciences market.
LAB - Share of the company's market capitalization Standard BioTools Inc. within the market segment - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative instruments for biomedical research, particularly for single-cell analysis. Its share of its segment's market capitalization reflects its technological leadership in this niche. The chart below shows how investors assess its potential in areas such as oncology and immunology.
Market capitalization of the market segment - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative biological research instruments that enable the analysis of individual cells. The chart below shows the market capitalization of the medical analysis sector. This is an estimate of a market where technology is changing our understanding of biology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Standard BioTools, formerly known as Fluidigm, produces innovative instruments for biological research at the single-cell level. The company's market capitalization reflects the value of its technologies to scientists in the pharmaceutical and academic fields. Its market share reflects the weight of its equipment, which enables scientific discoveries unseen using older methods.
Book value capitalization of the company, segment and market as a whole
LAB - Book value capitalization of the company Standard BioTools Inc.
Standard BioTools is built on high-tech manufacturing. Formerly known as Fluidigm, the company's book value reflects its patents and manufacturing facilities for cytometry and proteomics instruments used in biomedical research. The chart below shows how the company manages its high-tech manufacturing foundation.
LAB - Share of the company's book capitalization Standard BioTools Inc. within the market segment - Medanalysis
Standard BioTools manufactures biological research instruments at its own manufacturing facilities. This scientific and industrial infrastructure is its key tangible asset. The S_BCap_Seg chart shows its share of the medical analysis sector's physical assets.
Market segment balance sheet capitalization - Medanalysis
The life sciences industry, as the chart shows, requires unique assets. Standard BioTools (formerly Fluidigm) is a prime example. Its business is capital-intensive, requiring manufacturing capabilities to create complex biological analysis instruments.
Book value of all companies included in the broad market index - GURU.Markets
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research at the single-cell level. The company's assets include factories that create "21st-century microscopes" for scientific laboratories. The chart below shows the financial weight behind this biomedical technology provider.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Standard BioTools Inc.
Standard BioTools' balance sheet consists of its biological research equipment manufacturing plants. The market evaluates the company based on the value of its unique technologies and its history of financial difficulties. The chart below shows how investors value this technologically advanced but troubled player.
Market to book capitalization ratio in a market segment - Medanalysis
Standard BioTools Inc. produces biological research instruments that enable the analysis of individual cells. Its value lies in its unique technology. This chart shows how its market valuation, reflecting the scientific potential of its instruments, relates to its tangible assets.
Market to book capitalization ratio for the market as a whole
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research, particularly in the field of single-cell analysis. The company's value lies in its unique technology and patents. This chart shows how investors assess its scientific potential and ability to compete in the high-tech laboratory equipment market.
Debts of the company, segment and market as a whole
LAB - Company debts Standard BioTools Inc.
Standard BioTools, formerly Fluidigm, a manufacturer of biological research instruments, is managing its balance sheet amidst a restructuring and strategic shift. This chart shows how the company, following its merger and rebranding, is optimizing its finances to focus on more promising products and achieve profitability.
Market segment debts - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research. The company is undergoing transformation and restructuring. This chart shows how its debt policy reflects these changes and how it manages its capital to fund new product development and return to growth in the biotechnology equipment market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Standard BioTools Inc.
Standard BioTools develops and manufactures instruments for biological research. This is a high-tech sector that requires continuous investment in R&D to remain competitive. This chart shows how the company uses financial instruments to fund its innovation and operations.
Market segment debt to market segment book capitalization - Medanalysis
Standard BioTools (formerly Fluidigm) produces instruments and reagents for biotechnology research, particularly in the field of single-cell analysis. This chart compares its debt to the overall market capitalization of the entire sector. It shows how this company, operating at the forefront of science, funds its innovations and manages its financial position.
Debt to book value of all companies in the market
Standard BioTools, formerly Fluidigm, produces innovative instruments for biological research. In the biotechnology equipment sector, R&D and commercialization of new products require constant investment. This graph of total market debt provides insight into the financial environment in which the company strives for technological leadership and seeks paths to profitability.
P/E of the company, segment and market as a whole
P/E - Standard BioTools Inc.
This metric for Standard BioTools Inc. (formerly Fluidigm), a manufacturer of biotech research instruments, reflects the valuation of its mass cytometry and microfluidics technologies. Profitability depends on R&D spending in the scientific community. The chart shows how investors value its technology base after the restructuring period.
P/E of the market segment - Medanalysis
Standard BioTools, formerly known as Fluidigm, develops and manufactures innovative instruments for biological research. The company's technologies enable scientists to analyze cells and tissues at the microscopic level. This chart illustrates the average rating in the biomedical analysis sector, which values technological leadership and contribution to scientific discovery.
P/E of the market as a whole
Standard BioTools (formerly Fluidigm) produces innovative biological research instruments for the analysis of individual cells. This chart reflects the overall sentiment in the biotech sector. Comparisons with it help understand how the market views the company's restructuring efforts and its ability to commercialize its cutting-edge, yet complex, technologies in a highly competitive environment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Standard BioTools Inc.
The Standard BioTools chart shows how the market estimates the company's future revenue from sales of its biological research instruments. This metric reflects analysts' expectations for demand for cell and protein analysis technologies from pharmaceutical companies and academic laboratories.
%20P%2FE%20Standard%20BioTools%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Standard-BioTools-Inc.&v=1772513458982 "Chart of the company's future (projected) P/E Standard BioTools Inc.")
Future (projected) P/E of the market segment - Medanalysis
Standard BioTools Inc. produces instruments and reagents for biomedical research. This chart shows average expectations for the medical analysis sector. LAB's position may indicate how investors view the demand for its technologies from research labs and pharmaceutical companies, as well as its ability to innovate.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772513458990 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Standard BioTools (LAB) produces instruments for biological research. Demand for its products depends on scientific funding and pharmaceutical companies' R&D budgets. General market optimism, reflected in this chart, is driving increased investment in research and development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513458992 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Standard BioTools Inc.
Standard BioTools Inc. (formerly Fluidigm) produces innovative biological research instruments that enable the analysis of individual cells. This chart shows how the company is monetizing cutting-edge science. Growing revenue will mean its microfluidics and mass cytometry technologies become the standard in pharmaceutical research and academic labs.
Profit of companies in the market segment - Medanalysis
Standard BioTools Inc., formerly known as Fluidigm, produces innovative tools for biological research. Profitability in the medical analytics sector, as this chart shows, depends on R&D budgets at pharmaceutical companies and academia. LAB's products accelerate discovery, creating strong demand for their technologies.
Overall market profit
Standard BioTools, formerly Fluidigm, produces instruments for biological research. Demand for its products depends on R&D budgets at pharmaceutical companies and academic institutions. These budgets, in turn, depend on the overall economic situation, as reflected in this graph. During periods of growth, research funding increases, stimulating the company's sales.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Standard BioTools Inc.
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research. This chart shows the company's revenue forecast, which is influenced by research budgets at biotech and pharmaceutical companies. Analyst expectations reflect demand for advanced cell and gene analysis technologies.
%20profit%20of%20the%20company%20Standard%20BioTools%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Standard-BioTools-Inc.&v=1772513458998 "Graph of future (projected) profit of the company Standard BioTools Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
Standard BioTools Inc., formerly known as Fluidigm, produces innovative biological research instruments that analyze cells and tissues at the microscopic level. This chart shows the revenue forecast for the medical analysis sector, reflecting research spending expectations for pharmaceutical and biotech companies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772513458998 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Standard BioTools Inc. (formerly Fluidigm) produces instruments for biological research. Demand for its products depends on the budgets of academic institutions and biotech companies, which, in turn, rely on government funding and venture capital. A negative market outlook could complicate fundraising for its customers and slow down equipment procurement.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513459001 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Standard BioTools Inc.
Standard BioTools, formerly known as Fluidigm, produces innovative instruments for biological research, particularly for single-cell analysis (proteomics and genomics). Its revenue depends on the budgets of scientific laboratories and pharmaceutical companies. The chart shows how the market values its cutting-edge technologies and their potential to accelerate scientific discovery.
P/S market segment - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative biological research instruments that analyze individual cells and tissues. The chart shows the average revenue estimate for the biomedical equipment sector. It helps assess how investors perceive its technology and its potential in the scientific research market.
P/S of the market as a whole
Standard BioTools Inc. (formerly Fluidigm) produces innovative biological research instruments that enable scientists to analyze cells and tissues at the microscopic level. Its revenue is driven by research budgets. This chart helps understand the market's value proposition for this supplier of sophisticated equipment for the science-intensive industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Standard BioTools Inc.
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research, particularly in the field of single-cell analysis. This chart reflects investor valuation of its technologies, based on projected future sales of its equipment and reagents to scientific laboratories and pharmaceutical companies.
%20P%2FS%20Standard%20BioTools%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Standard-BioTools-Inc.&v=1772513459018 "The graph of the company's future (projected) P/S Standard BioTools Inc.")
Future (projected) P/S of the market segment - Medanalysis
Standard BioTools, formerly known as Fluidigm, produces innovative instruments for biological research, including single-cell analysis systems. This chart shows the average estimated future revenue for companies in the medical analysis sector. It provides insight into the market's perception of laboratory demand for Standard BioTools' high-tech equipment.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772513459020 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Standard BioTools Inc. produces instruments for biological research. Its clients are scientific laboratories and pharmaceutical companies. Demand for its products depends on R&D budgets, not the general economic cycle. This revenue expectation schedule is secondary to its expectations. The key driver is the pace of innovation in biotechnology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513459020 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Standard BioTools Inc.
Standard BioTools (formerly Fluidigm) develops and manufactures innovative instruments for biological research. Its revenue, reflected in this chart, is generated by sales of instruments and consumables for scientists in the fields of genomics and proteomics. Sales growth reflects demand for its technologies from scientific laboratories and pharmaceutical companies.
Sales of companies in the market segment - Medanalysis
Standard BioTools Inc., formerly known as Fluidigm, develops and manufactures innovative instruments for biological research. Their technologies, such as mass cytometry, enable scientists to conduct in-depth analysis of individual cells. This chart shows the sector's total revenue, reflecting the level of investment in biotechnology research and development.
Overall market sales
Standard BioTools Inc., formerly known as Fluidigm, produces innovative instruments for biological research. This chart shows the overall economy, but for LAB, the key drivers are research and development (R&D) spending by pharmaceutical companies and academic institutions. These are investments in the future of medicine, not always tied to the current market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Standard BioTools Inc.
Standard BioTools, formerly known as Fluidigm, produces innovative instruments for biological research, particularly in proteomics and genomics. Demand for its products is driven by research budgets. This chart shows the expected adoption of its advanced analytical systems in laboratories worldwide.
%20sales%20of%20the%20company%20Standard%20BioTools%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Standard-BioTools-Inc.&v=1772513459033 "Schedule of future (projected) sales of the company Standard BioTools Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
Standard BioTools, formerly known as Fluidigm, develops and manufactures innovative instruments and reagents for biological research. Its technologies enable scientists to analyze cells and tissues with high accuracy. The chart shows forecasts for the medical analysis sector. The company's success depends on investment in research and development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772513459034 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Standard BioTools (formerly Fluidigm) produces innovative biotechnology research equipment for single-cell analysis. Demand for its products depends on the budgets of scientific laboratories and pharmaceutical companies. This dynamic, reflecting overall economic activity, influences R&D funding, which directly impacts the purchase of new equipment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513459035 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Standard BioTools Inc.
Standard BioTools, formerly Fluidigm, produces innovative instruments for biotechnology research. The company's profitability depends on sales of its sophisticated equipment and consumables to scientific laboratories. This chart shows how the company is turning its cutting-edge cell and protein analysis technologies into commercial success.
Market segment marginality - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative systems for biomedical research, particularly in single-cell analysis. This chart shows the average profitability in the life sciences sector. Leadership in advanced analysis technologies gives the company the potential to achieve high margins, exceeding the industry average.
Market marginality as a whole
Standard BioTools Inc. produces instruments and reagents for biological research, particularly in proteomics and genomics. Its clients include scientific laboratories and pharmaceutical companies. Compared to overall corporate profitability, this business demonstrates how scientific technology providers depend on R&D funding.
Employees in the company, segment and market as a whole
Number of employees in the company Standard BioTools Inc.
Standard BioTools creates sophisticated instruments for biomedical research. Its team consists of scientists, engineers, and a highly specialized sales team. This chart reflects the company's investment in R&D and the commercial infrastructure necessary to sell its equipment to laboratories worldwide.
Share of the company's employees Standard BioTools Inc. within the market segment - Medanalysis
Standard BioTools (formerly Fluidigm) produces innovative instruments for biological research, enabling scientists to analyze cells and tissues with high precision. It's a science-intensive business. This chart shows the percentage of specialists in the biotechnology equipment niche the company attracts. It reflects its scientific stature and the team behind its cutting-edge technologies.
Number of employees in the market segment - Medanalysis
Standard BioTools Inc., formerly Fluidigm, produces innovative biotech tools for academic and pharmaceutical research. The headcount chart reflects the product development and commercialization cycles. The growth of engineering and sales staff is driven by the launch of new platforms that are being applied in cutting-edge science.
Number of employees in the market as a whole
Standard BioTools Inc. produces instruments for biological research. Its clients include scientific laboratories and pharmaceutical companies. This overall workload only indirectly impacts its business through its overall research funding. Its primary drivers are advances in research and the need for more accurate and faster analytical instruments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Standard BioTools Inc. (LAB)
Standard BioTools Inc. produces instruments for biological research. It's a knowledge-intensive business, where its core value lies in technology and patents. This chart shows a high intellectual capital valuation. Each employee accounts for a significant portion of the value of unique developments.
%20of%20the%20company%20Standard%20BioTools%20Inc.%20(LAB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Standard-BioTools-Inc.-LAB&v=1772513459057 "Chart of market capitalization per employee (in thousands of dollars) of the company Standard BioTools Inc. (LAB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Standard BioTools Inc., formerly known as Fluidigm, produces innovative instruments for biological research. It's a high-tech business where value is created by a team of scientists and engineers. This chart shows how the market values the company's intellectual capital and technology per employee.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772513459059 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Standard BioTools (formerly Fluidigm) develops and manufactures instruments for biological research. This chart shows the valuation of the Life Science sector. It reflects how the market values the contribution of its teams of engineers and scientists to the creation of complex equipment used in laboratories around the world to drive scientific discovery.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513459062 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Standard BioTools Inc. (LAB)
Standard BioTools (formerly Fluidigm) produces instruments for biotechnology research, specializing in single-cell analysis. This high-tech scientific equipment is essential for scientific research. This chart shows how profitable their business of manufacturing and selling these instruments is. It measures how much net profit each employee, from R&D engineer to sales specialist, generates.
%20Chart%20Standard%20BioTools%20Inc.%20(LAB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Standard-BioTools-Inc.-LAB&v=1772513459066 "Company Profit Per Employee (in thousands of dollars) Chart Standard BioTools Inc. (LAB)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Standard BioTools (LAB) is a "Life Science Tools" company (proteomics equipment). This chart shows the benchmark for "Med-analysis" (Life Science Tools). The average profit per employee here is high (or negative if it's R&D). It's a "razor and blade business." The benchmark reflects stable, high-margin revenue from "blades" (consumables).
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772513459068 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Standard BioTools (LAB) produces instruments and reagents for biomedical research (cytometry, genomics). This business supplies the building blocks of science and pharmaceuticals. It requires R&D and complex manufacturing. This graph shows the profit generated by each employee creating high-tech laboratory equipment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513459069 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Standard BioTools Inc. (LAB)
Standard BioTools Inc. produces instruments for biological research. This chart shows how the company is commercializing its complex technologies. The growth in revenue per employee reflects the demand for its equipment from scientific laboratories and pharmaceutical companies, as well as the effectiveness of its sales team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Standard-BioTools-Inc.-LAB&v=1772513459071 "Sales chart per company employee Standard BioTools Inc. (LAB)")
Sales per employee in the market segment - Medanalysis
Standard BioTools (LAB), formerly Fluidigm, produces innovative equipment (microfluidics, mass cytometry) for biotech research. These are complex scientific instruments. This graph demonstrates their commercial effectiveness. Selling expensive equipment and its consumables allows for high revenue generation per employee in R&D and sales.
Sales per employee for the market as a whole
Standard BioTools (formerly Fluidigm) produces instruments for biotechnology research. This is a science-intensive instrumentation company. This metric reflects how effectively the company sells its complex and expensive analytical systems. It demonstrates the impact of its R&D and sales teams working with laboratories.
Short shares by company, segment and market as a whole
Shares shorted by company Standard BioTools Inc. (LAB)
Standard BioTools (LAB) is a company that produces microfluidics and mass cytometry instruments. This sophisticated laboratory equipment allows scientists to analyze individual cells. This chart shows bearish bets. Bears may doubt the demand for their expensive equipment or the success of the company's recent strategic changes.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Standard-BioTools-Inc.-LAB&v=1772513459079 "Short Shares Chart for the Company Standard BioTools Inc. (LAB)")
Shares shorted by market segment - Medanalysis
Standard BioTools (LAB) (formerly Fluidigm) is a company that produces high-tech equipment (cytometers, microfluidics) for bioresearch. This chart shows bets against the "scientific equipment" sector. Its rise reflects concerns that R&D budgets of pharmaceutical companies and laboratories (LAB's clients) will be cut due to the recession.
Shares shorted by the overall market
Standard BioTools (LAB) (formerly Fluidigm) produces innovative equipment for biological research (single-cell analysis). Its clients are scientific laboratories. This chart reflects the overall market pessimism. When investors are fearful (the indicator is rising), they may fear that a recession will cut research budgets (grants, R&D), which will reduce demand for expensive LAB equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Standard BioTools Inc. (LAB)
Standard BioTools (formerly Fluidigm) produces instruments for biomedical research. The business depends on R&D budgets. A reading above 70 may reflect strong demand from the biotech sector. A reading below 30 may signal concerns about R&D budget cuts (a "venture winter") or company problems.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Standard-BioTools-Inc.-LAB&v=1772513459097 "RSI 14 indicator chart for the company's stock Standard BioTools Inc. (LAB)")
RSI 14 Market Segment - Medanalysis
Standard BioTools (formerly Fluidigm) supplies sophisticated instruments for biomedical research, specializing in mass cytometry and microfluidics technologies. It's "hardware" for science. This chart measures the collective momentum in the life science tools sector. It reveals whether the entire biotech sector is overheated or whether investors are evaluating the LAB technology niche.
RSI 14 for the overall market
Standard BioTools (LAB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LAB (Standard BioTools Inc.)
Standard BioTools (LAB), formerly known as Fluidigm, develops and manufactures advanced instruments (cytometers, mass spectrometers) for biomedical research. These devices enable in-depth analysis of individual cells. This chart shows the average analyst forecast, reflecting their assessment of demand for research equipment from pharmaceutical companies and laboratories.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LAB-Standard-BioTools-Inc.&v=1772513459137 "A chart showing analyst consensus forecasts for the expected stock price. LAB (Standard BioTools Inc.)")
The difference between the consensus estimate and the actual stock price LAB (Standard BioTools Inc.)
Standard BioTools (formerly Fluidigm) is a manufacturer of high-tech instruments (mass cytometers) for in-depth analysis of individual cells and tissues. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the implementation of their sophisticated research technologies in labs around the world.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LAB-Standard-BioTools-Inc.&v=1772513459152 "A chart showing the difference between the consensus forecast and the actual stock price. LAB (Standard BioTools Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Standard BioTools (LAB) is a manufacturer of high-tech biological research tools (cytometry, proteomics), which allow scientists to analyze living cells. This chart shows analysts' overall expectations for the medical testing sector. It reflects whether experts believe R&D budgets in biotech will grow.
Analysts' consensus forecast for the overall market share price
Standard BioTools (LAB) is the purveyor of the biotech revolution. They produce instruments (cytometers) for R&D. This chart of overall market sentiment is important. Optimism = biotechs easily raise money and spend it on R&D (buying LAB equipment). Pessimism = venture winter = R&D freeze.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Standard BioTools Inc.
Standard BioTools (formerly Fluidigm) is a company that creates instruments for biological research. Their technologies (microfluidics, mass cytometry) allow scientists to analyze individual cells and proteins. This chart is an assessment of their technological reboot. It reflects their ability to commercialize their complex instruments and their transition from R&D to more stable sales.
AKIMA Market Segment Index - Medanalysis
Standard BioTools (LAB) (formerly Fluidigm) is a leader in bioscience instruments; after its merger with SomaLogic, the company produces unique equipment (CyTOF) and proteomics for single-cell analysis. This summary metric evaluates R&D. The graph shows the sector average. This benchmark: how does this high-tech (R&D instruments) model (LAB) differentiate it from the average medtech competitor?
The AKIM Index for the overall market
Standard BioTools (formerly Fluidigm) is a manufacturer of mass cytometry and genomics instruments. They're the "picks and shovels" of biological research. This chart, reflecting the market average, is just the background. It helps assess how the laboratory, which relies on academic and pharmaceutical R&D budgets, stacks up against the backdrop of overall macroeconomic fluctuations.
